UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT PURSUANT
TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported):
June 19, 2015
ABEONA THERAPEUTICS INC.
(Exact name of registrant as specified in
its charter)
| Delaware |
0-9314 |
83-0221517 |
| (State or other jurisdiction of incorporation) |
(Commission File Number) |
(I.R.S. Employer Identification No.) |
| |
|
|
3333 Lee Parkway, Suite 600, Dallas,
TX 75219
(Address of principal
executive offices) (Zip Code)
(214) 665-9495
(Registrant’s telephone number, including
area code)
PLASMATECH BIOPHARMACEUTICALS, INC.
4848 Lemmon Avenue, Suite 517, Dallas,
TX 75219
(Former name or former address, if changed
since last report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| o | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
o Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 5.03. Amendments to
Articles of Incorporation or Bylaws; Change in Fiscal Year.
On June 19, 2015, PlasmaTech Biopharmaceuticals,
Inc. (the “Company”) filed in Delaware a Certificate of Amendment of
Certificate of Incorporation to change our name from PlasmaTech Biopharmaceuticals, Inc. to Abeona Therapeutics Inc. A copy of
the Certificate of Amendment of Certificate of Incorporation is filed as Exhibit 3.1 with this Form 8-K and incorporated herein
by reference.
Item 8.01. Other Events
On June 19, 2015, the Company issued a
press release announcing that the Company had changed its name from PlasmaTech Biopharmaceuticals, Inc. to Abeona Therapeutics
Inc. and its trading symbol from PTBI to ABEO.
A copy of the press release is furnished
as Exhibit 99.1 and is incorporated by reference.
Item 9.01. Financial Statements
and Exhibits.
(d) Exhibits.
The Company hereby
furnishes the following exhibits:
| 3.1 | Certificate of Amendment of Certificate
of Incorporation filed June 19, 2015 |
| 99.1 | Press release dated June 19, 2015, entitled “PlasmaTech Biopharmaceuticals Announces Name
Change to Abeona Therapeutics” |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act
of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| |
Abeona Therapeutics Inc. |
| |
(Registrant) |
| |
|
|
| |
By: |
/s/ Stephen B. Thompson |
| |
Stephen B. Thompson |
| |
Vice President Finance |
Date: June 19, 2015
EXHIBIT INDEX
Exhibit Number
| 3.1 | Certificate of Amendment of Certificate
of Incorporation filed June 19, 2015 |
| 99.1 | Press release dated June 19, 2015, entitled “PlasmaTech
Biopharmaceuticals Announces Name Change to Abeona Therapeutics” |
Exhibit 3.1
EXHIBIT 99.1
PlasmaTech Biopharmaceuticals
Announces Name Change to Abeona Therapeutics to Reflect
Broader Rare
Disease Commitment
| · | Abeona Therapeutics is focused on developing and delivering gene therapy and plasma-based products
for severe and life-threatening rare diseases |
| · | Established next generation AAV-based gene therapy platform led by four rare, autosomal recessive
(inherited) orphan pediatric disease product candidates in development |
| · | Acquired CRISPR-Cas9 gene-editing system with first lead product developed and ongoing research
in multiple rare blood disease targets |
| · | Developing novel SDF™ plasma-based platform led by SDF Alpha™ (alpha1 antitrypsin)
for inherited form of COPD (chronic obstructive pulmonary disease) and other orphan protein therapeutics |
New York, NY, June 19 2015 –
PlasmaTech Biopharmaceuticals, Inc. (Nasdaq: PTBI), a biopharmaceutical company focused on developing and delivering gene therapy
and plasma-based products for severe and life-threatening rare diseases, today announced
a name change to Abeona Therapeutics, Inc. to reflect its broader rare disease commitment. The Company expects that its
common stock will begin trading on NASDAQ on Monday, June 22, under the ticker symbol ABEO, along with announcing Abeona Therapeutics
to ring the Nasdaq Stock market closing bell on Monday, June 22nd at 4:00 pm ET. Live streaming can be found at: https://new.livestream.com/nasdaq/live)
“Abeona was forged from the company’s
close collaborations with key stakeholders, all dedicated to transforming new biotechnology insights into breakthrough treatments
for rare diseases,” stated Steven Rouhandeh, Executive Chairman. “Most importantly, we have established a dedicated
team of world class professionals led by Dr. Tim Miller, who will be critical to building and accelerating value for patients and
shareholders.”
A rare disease is one that affects
fewer than 200,000 people in the United States. There are nearly 7,000 rare diseases, which may involve chronic illness, disability,
and often, premature death. More than 25 million Americans and 30 million Europeans have a rare disease. While rare diseases can
affect any age group, about 50% of people affected are children (15 million); and rare diseases account for 35% of deaths in the
first year of life. These rare diseases are often poorly diagnosed, very complex, and have no treatment or not very effective treatment—over
95% of rare diseases do not have a single FDA or EMA approved drug treatment. However, most rare diseases are often caused by changes
in genes—80% are genetic in origin and can present at any stage of life.
“Effectively developing therapies
for rare disease requires innovative approaches and strong collaboration between researchers, industry, regulators and patient
groups,” noted Tim Miller, Ph.D., President & CEO. “We believe emerging insights in gene therapy and advances in
biotechnology provide significant opportunities to develop breakthrough treatments for rare diseases. Our focus is transforming
the promise of our products and platforms into new treatments for severe and life-threatening rare diseases such as Sanfilippo
syndromes types A and B, juvenile Batten disease, and Fanconi anemia.”
About the Abeona Name Change: Abeona
(pronounced ey-bee-ohn-uh) is the Roman Goddess who protects children as they take their first steps away
from home.
About Abeona Therapeutics, Inc.:
Abeona Therapeutics is focused on developing and delivering gene therapy and plasma-based products for severe and life-threatening
rare diseases. Abeona’s lead program is an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome (MPS IIIA
and IIIB) in collaboration with patient advocate groups, researchers and clinicians. Clinical trials for Sanfilippo types A and
B are anticipated to begin in 2015. The Company recently licensed an AAV-based gene therapy program in juvenile Batten disease
(JBD) from the University of Nebraska Medical Center; and licensed an AAV-based gene therapy program for Fanconi anemia (FA) disorder
and other rare blood diseases using CRISPR/Cas9 gene editing from the University of Minnesota. In addition, the company is pursuing
two additional proprietary platforms, Salt Diafiltration (SDF™) Process and Polymer Hydrogel Technology (PHT™), and
is active in the development and commercialization of human plasma-derived therapeutics, including its proprietary alpha-1 protease
inhibitor, SDF Alpha™. For more information, visit www.abeonatherapeutics.com.
Company and Media Contact:
Andre’a Lucca
Director of Communications
Abeona Therapeutics, Inc.
+1 (212)-786-6208
alucca@abeonatherapeutics.com
This press release contains certain
statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, and that involve
risks and uncertainties. These statements include, without limitation, development and internationalization of clinical programs,
information regarding the future performance of the combined company, the outlook on medical needs, future pipeline expectations,
management plans for the Company, the anticipated closing of the transaction, and general business outlook. These statements are
subject to numerous risks and uncertainties, including but not limited the satisfaction of closing conditions for the transaction,
the parties' ability to successfully integrate and operate the new company, and achieve expected synergies and other benefits;
the impact of competition; the ability to develop products and technologies; the ability to achieve or obtain necessary regulatory
approvals; the impact of changes in the financial markets and global economic conditions; and other risks as may be detailed from
time to time in the Company's Annual Reports on Form 10-K and other reports filed by the Company with the Securities and Exchange
Commission. The Company undertakes no obligations to make any revisions to the forward-looking statements contained in this release
or to update them to reflect events or circumstances occurring after the date of this release, whether as a result of new information,
future developments or otherwise.
PlasmaTech Biopharmaceuticals, (NASDAQ:PTBI)
Graphique Historique de l'Action
De Oct 2024 à Déc 2024
PlasmaTech Biopharmaceuticals, (NASDAQ:PTBI)
Graphique Historique de l'Action
De Déc 2023 à Déc 2024
